ReviewMayo Clinic proceedings2010
Managing aromatase inhibitors in breast cancer survivors: not just for oncologists.
Review in Mayo Clinic proceedings, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Pooled it
- Racial/Ethnic and socioeconomic disparities in endocrine therapy adherence in breast cancer: a systematic review.American journal of public health · 2015Pooled it
- Hormones as a double-edged sword: the role of hormones in cancer progression and the potential of targeted hormone therapies.Medical oncology (Northwood, London, England) · 2024Review
- Design, synthesis, molecular docking andRSC advances · 2024Article
- Is the percentage of hormone receptor positivity in HR+ HER2-metastatic breast cancer patients receiving CDK 4/6 inhibitor with endocrine therapy predictive and prognostic?Frontiers in oncology · 2024Article
- Escitalopram co-prescription in anastrozole-treated breast cancer patients.Northern clinics of Istanbul · 2022Article
- Physical activity and health-related quality of life among postmenopausal women with breast cancer treated with aromatase inhibitors.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2021Article
- Clinical Challenges in the Management of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: A Literature Review.Advances in therapy · 2021Review
- Risk of dementia among postmenopausal breast cancer survivors treated with aromatase inhibitors versus tamoxifen: a cohort study using primary care data from the UK.Journal of cancer survivorship : research and practice · 2019Article
- Investigation of genotoxicity risk and DNA repair capacity in breast cancer patients using anastrozole.Northern clinics of Istanbul · 2018Article
- Dietary Guidelines for Breast Cancer Patients: A Critical Review.Advances in nutrition (Bethesda, Md.) · 2017Review
- Oncology providers' perspectives on endocrine therapy prescribing and management.Patient preference and adherence · 2016Article
- Aromatase Inhibitor-Induced Erythrocytosis in a Patient Undergoing Hormonal Treatment for Breast Cancer.Case reports in hematology · 2015Article
- Caring for the breast cancer survivor's health and well-being.World journal of clinical oncology · 2014Review
- Challenges in the gynecologic care of premenopausal women with breast cancer.Mayo Clinic proceedings · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The role of the general internist in the care of breast cancer survivors is increasing as the number of women living with breast cancer continues to rise. Most breast cancers occurring in women older than 50 years are estrogen receptor- and/or progesterone receptor-positive, and adjuvant endocrine therapy plays an important role in the treatment plan. Aromatase inhibitors are becoming the preferred endocrine therapy, and general internists caring for breast cancer survivors need to be familiar with their use and adverse effect profile. This article reviews the use of aromatase inhibitors, the frequency of common adverse effects, and strategies for their management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.